[Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control].
OBJECTIVE
To evaluate tolerance to lixisenatide and its effects on weight and metabolic control in type2 diabetes and obese patients.


METHODS
Prospective study.


METHODS
Endocrinology clinics in Almeria, Granada and Malaga.


METHODS
Patients with type2 diabetes and obesity.


METHODS
Response and tolerance to lixisenatide treatment.


METHODS
Clinical and analytical data of the subjects were evaluated at baseline and after treatment.


RESULTS
The study included 104 patients (51% women) with type2 diabetes and obesity (Almeria 18.3%; Granada 40.4%; Malaga 41.3%). The mean age was 58.4±10.5years, and the mean duration of diabetes was 11.2±6.7years. The patients were re-evaluated at 3.8±1.6months after treatment with lixisenatide. Significant improvements were found in weight (P<.001), body mass index (P<.001), waist circumference (P=.002), systolic blood pressure (P<.001), diastolic blood pressure (P=.001), fasting glucose (P<.001), HbA1c (P=.022), Total cholesterol (P<.001), LDL-cholesterol (P=.046), triglycerides (P=.020), hypertension drugs (P<.001), and lipids drugs (P<.001). No changes were observed in levels of amylase related to lixisenatide treatment, and 7.9% of patients did not tolerate it.


CONCLUSIONS
Lixisenatide achieved signiﬁcant improvements in anthropometric parameters, glycaemic control (fasting glucose and HbA1c), blood pressure and lipids. It was safe and well tolerated in most patients. In addition, there was a significant increase in the use of antihypertensive and lipid-lowering therapy.
UGC de Endocrinología y Nutrición, Hospital Universitario Puerta del Mar, Cádiz, España. Electronic address: maroca80@gmail.com.
M Mar
MM
Roca-Rodríguez
UGC de Endocrinología y Nutrición, Hospital Virgen de las Nieves, Granada, España.
María Teresa
MT
Muros de Fuentes
UGC de Endocrinología y Nutrición, Hospital Virgen de las Nieves, Granada, España.
Gonzalo
G
Piédrola-Maroto
UGC de Endocrinología y Nutrición, Hospital San Cecilio, Granada, España.
Miguel
M
Quesada-Charneco
UGC de Endocrinología y Nutrición, Hospital Clínico Universitario Virgen de la Victoria y Hospital Regional Universitario, Málaga, España.
Silvia
S
Maraver-Selfa
UGC de Endocrinología y Nutrición, Hospital Clínico Universitario Virgen de la Victoria y Hospital Regional Universitario, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA), Complejo Hospitalario de Málaga (Virgen de la Victoria)/Universidad de Málaga; CIBER Pathophysiology of Obesity and Nutrition (CB06/03), Málaga, España.
Francisco J
FJ
Tinahones
UGC de Endocrinología y Nutrición, Hospital Clínico Universitario Virgen de la Victoria y Hospital Regional Universitario, Málaga, España.
Isabel
I
Mancha-Doblas
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D010455:Peptides / Q000627:therapeutic use*; D011446:Prospective Studies; D000067758:Glucagon-Like Peptide-2 Receptor
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D010455:Peptides; C479460:lixisenatide; D000067758:Glucagon-Like Peptide-2 Receptor
Análogos de GLP-1; Control metabólico; Diabetes tipo2; GLP-1; Lixisenatida; Lixisenatide; Metabolic control; Obesidad; Obesity; Type 2 diabetes
BMJ Open. 2013 Jan 24;3(1):null
23355666
BMJ Open. 2014 Dec 19;4(12):e005325
25526792
JAMA. 2007 Jul 11;298(2):194-206
17622601
Curr Diab Rep. 2015 Nov;15(11):87
26370698
Can J Diabetes. 2014 Oct;38(5):364-71
25284699
Diabetes Care. 2013 Oct;36(10):2945-51
23698396
Drug Saf. 2014 Dec;37(12):1003-10
25391858
J Endocrinol Invest. 2013 Mar;36(3):168-73
22522662
Diabetes Metab Res Rev. 2014 Jul;30(5):354-71
24989141
J Med Econ. 2015;18(12):1029-31
26337323
Practitioner. 2015 Jan;259(1778):25-8, 3
25726618
Trends Endocrinol Metab. 2013 Feb;24(2):85-91
23332584
Diabetes Obes Metab. 2013 Jul;15(7):642-9
23368510
Diabetes Care. 2015 Jul;38(7):1263-73
25887358
Diabetes Obes Metab. 2012 Sep;14(9):810-20
22486990
Drugs Context. 2015 Jul 09;4:212283
26213556
Heart Lung Circ. 2014 Nov;23(11):997-1008
24996388